Ram's questions to Anavex Life Sciences Corp (AVXL) leadership • Q3 2025
Question
Ram from H.C. Wainwright & Co. asked which European countries are most important commercially for blarcamesine, whether safer anti-amyloid antibodies reduce the need for an oral option, and when the company might disclose additional orphan indications for blarcamesine.
Answer
President & CEO Dr. Christopher Missling identified Germany, France, and Italy as the key European markets. He asserted that despite advancements in injectable antibodies, a survey confirmed an 'extremely high preference' for an oral solution like blarcamesine in Europe due to the complexities and low adoption of injectables by general practitioners and neurologists. Dr. Missling also stated that Anavex is planning a study in another rare disease with an orphan designation and will disclose the indication once it is further along.